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Background
The Cancer Immunotherapy Trials Network is conduct-
ing a Phase I, dose-escalation study of subcutaneous
(SQ) rhIL-15 in advanced melanoma, renal cell, non-
small cell lung (NSCLC) and squamous cell head and
neck carcinoma patients. IL-15 has been identified as a
high priority agent for immunotherapy development
because it is a homeostatic factor for both NK cells and
CD8+ T cells and, unlike IL-2, has little effect on sup-
pressive regulatory T cells.
Methods
Each cycle consists of 5 daily SQ injections of rhIL-15
(E.coli-derived, NCI) administered Monday-Friday for
two weeks, followed by 2 weeks observation. The abso-
lute lymphocyte count is tested every injection day, and
whole blood flow cytometric analysis of T and NK cell
frequencies is conducted on Days 1, 11 and 15 of each
cycle.
Results
Three patients have been enrolled in each of the 0.25,
0.5, 1.0 and 3.0 mcg/kg dose cohorts and six at
2.0 mcg/kg (N=18). Fourteen patients completed ≥2
cycles, three completed one cycle, and one patient (3
mcg/kg) received only 2 doses due to dose limiting toxi-
city (DLT). This last patient had NSCLC and developed
grade 3 chest pain, hypoxia and dyspnea leading to
hospitalization and discontinuation of rhIL-15. One ser-
ious adverse event, grade 2 pancreatitis, was observed in
a metastatic melanoma patient 3 days after completing
Cycle 1 (at 2.0 mcg/kg). Flow cytometric data indicate a
consistent increase in the frequency of CD56+CD3-NK
cell frequencies peaking at Day 15 of Cycle 1 (3 days
after the last dose), with lesser increases in subsequent
cycles. The mean fold-increase in circulating NK cells
during Cycle 1 was 2.3, 3.3, 4.4, 9.6, and 11.8-fold for
the 0.25, 0.5, 1.0, 2.0 and 3.0 mcg/kg dose cohorts
respectively, demonstrating dose responsiveness. By con-
trast, the mean fold-increase in circulating CD8+ T cells
was relatively modest at 1.1, 0.9, 1.2, 3.3, and 3.2-fold
for the 0.25, 0.5, 1.0, 2.0 and 3.0 mcg/kg dose cohorts
respectively.
Conclusions
SQ rhIL-15 was well tolerated through 2.0 mcg/kg/dose
and may be the maximum tolerated dose. One of
3 patients treated with 3.0 mcg/kg rhIL-15 experienced a
DLT; this cohort will be expanded. Higher doses of
rhIL-15 were associated with profound increases in circu-
lating NK cells with smaller but still significant increases
in CD8+ T cells. Outpatient use of subcutaneous rhIL-15
is safe and will likely emerge as a key agent for combina-
tion with other cancer immunotherapies.
Study support: NIH 1U01 CA154967-01.
Trial registration
ClinicalTrials.gov identifier NCT01727076.1University of Washington, Seattle, WA, USA
Full list of author information is available at the end of the article
Morishima et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P203
http://www.immunotherapyofcancer.org/content/3/S2/P203
© 2015 Morishima et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ details
1University of Washington, Seattle, WA, USA. 2Department of Medicine,
University of Wisconsin-Madison, Madison, WI, USA. 3University of Minnesota,
Minneapolis, MN, USA. 4Stanford University, Stanford, CA, USA. 5National
Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
6Department of Human Oncology, Department of Pediatrics, University of
Wisconsin-Madison, Madison, WI, USA. 7Fred Hutchinson Cancer Research
Center, Seattle, WA, USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P203
Cite this article as: Morishima et al.: CITN11-02 interim trial results:
subcutaneous administration of recombinant human IL-15 (rhIL- 15) is
associated with expansion of peripheral blood CD56+ NK cells and CD8+
T cells. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P203.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Morishima et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P203
http://www.immunotherapyofcancer.org/content/3/S2/P203
Page 2 of 2
